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A reliable, non-invasive diagnostic method is needed for early detection and serial monitoring of 
cardiotoxicity, a well-known side effect of chemotherapy. This study aimed to assess the feasibility of 
T1-mapping cardiac magnetic resonance imaging (CMR) for evaluating subclinical myocardial changes in 
a doxorubicin-induced cardiotoxicity rabbit model. Adult male New Zealand White rabbits were injected 
twice-weekly with doxorubicin and subjected to CMR on a clinical 3T MR system before and every 2–4 
weeks post-drug administration. Native T1 and extracellular volume (ECV) values were measured at six 
mid-left ventricle (LV) and specific LV lesions. Histological assessments evaluated myocardial injury and 
fibrosis. Three pre-model and 11 post-model animals were included. Myocardial injury was observed 
from 3 weeks. Mean LV myocardium ECV values increased significantly from week 3 before LV ejection 
fraction decreases (week 6), and ECVs of the RV upper/lower insertion sites and papillary muscle 
exceeded those of the LV. The mean native T1 value in the mid-LV increased significantly increased 
from week 6, and LV myocardium ECV correlated strongly with the degree of fibrosis (r = 0.979, 
p < 0.001). Myocardial T1 mapping, particularly ECV values, reliably and non-invasively detected early 
cardiotoxicity, allowing serial monitoring of chemotherapy-induced cardiotoxicity.
Cardiotoxicity is a well-recognized adverse effect of chemotherapy1, 2. Notoriously, the anthracycline class of 
cytotoxic agents, which are highly effective against many cancers, can lead to irreversible myocardial damage3. 
In addition, considerable myocardial damage can occur below the known threshold level3–5. Accordingly, the 
early detection of myocardial dysfunction and prevention of overt heart failure are important3. Several guide-
lines and recommendations for cardiotoxicity monitoring have been published6, 7, including the American Heart 
Association (AHA)/American College of Cardiology (ACC) guidelines for anthracycline-induced cardiotoxic-
ity, which recommend the use of radionuclide imaging, including multi-gated acquisition (MUGA) scans, and 
echocardiography for ejection fraction monitoring8, 9. However, no other imaging modalities have been specified 
for cardiac function monitoring during anthracycline therapy. Accordingly, a reliable, non-invasive method is 
needed.
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Myocardial T1 mapping is a promising technique that could improve the detection of diffuse myocardial 
changes and quantitatively evaluate such changes using parameters such as T1 and extracellular volume (ECV) 
values. By measuring T1-mapping parameters, this novel technique confers the additional benefit of detecting 
myocardial changes caused by chemotherapy-induced cardiotoxicity at an earlier time point than would be 
available with other modalities10, 11. Accordingly, the purpose of this study was to assess the diagnostic value of 
T1-mapping cardiac magnetic resonance imaging (CMR) for evaluating early myocardial changes, to evaluate 
histopathology, and correlate the quantitative values obtained via CMR T1 mapping and histology of a rabbit 
model of cardiotoxicity.
Results
A total of 20 rabbits were included in this study. After 3 weeks of modelling, three rabbits were sacrificed for histo-
logical evaluation after CMR scanning. The remaining rabbits remained subject to modelling and CMR scanning, 
and two and four additional rabbits were sacrificed for histological evaluation after 6 and 12 weeks, respectively. 
Modelling continued in the remaining rabbits, which were subjected to CMR scans until the end of the 16-week 
modelling period, followed by sacrifice for histological evaluation. We note that four rabbits died of severe anae-
mia (n = 1) or infection (n = 3) during the modelling period. Figure 1 presents the experimental timeline and 
numbers of animals evaluated at each time point.
Physiological and functional data. Table 1 presents the physiological and functional data of the base-
line and experimental modelling groups. The left ventricle ejection fraction (LVEF, %) decreased significantly 
beginning at week 6 of modelling. The mean LVEF of the initial baseline group was 56.08 ± 5.80%, compared to 
44.59 ± 5.9% at week 6 of modelling (p < 0.001; Table 1). In addition to a decrease in left ventricle (LV) systolic 
function, a decrease in heart rate and morphologic LV changes, specifically chamber enlargement and wall thin-
ning, were noted in the rabbit model of cardiotoxicity.
Figure 1. Experimental timeline and numbers of animals evaluated at each time point. All rabbits underwent 
cardiac magnetic resonance imaging (CMR) before and every 2–4 weeks after drug administration. Circles 
indicate scanning CMR; black squares indicate sacrifice after CMR scanning. Crosses indicate unexpected 
deaths.
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T1 mapping CMR data. The ECV and native T1 values changed as the modelling period increased. The 
mean ECV values of the mid-LV increased relative to those of the baseline group and significantly increased 
beginning at week 3 (p = 0.002; Table 2, Fig. 2a). Compared with the LV myocardium, the ECV values of the right 
ventricle (RV) upper/lower insertion sites and papillary muscle were higher than those of the LV myocardium. 
The mean native T1 values in the mid-LV also increased according to the modelling time. The native T1 value 
of the 6-week model differed significantly from the baseline (p < 0.001; Table 2 and Fig. 2b). The inter-observer 
agreements were good, with intra-class correlation coefficients (ICCs) (95% confidence interval [CI]) of 0.951 
(0.919–0.971) for native T1 values, 0.958 (0.929–0.976) for the ECV of the LV myocardium, 0.915 (0.821–0.959) 
for the ECV of the RV upper insertion, 0.919 (0.830–0.961) for the ECV of the RV lower insertion, and 0.920 
(0.832–0.962) for the ECV of the papillary muscle.
Baseline subject Week 3 Week 6 Week 8 Week 10 Week 12 Week 16
(n = 16) (n = 6) (n = 10) (n = 6) (n = 7) (n = 8) (n = 4)
Weight (kg) 3.21 ± 0.40 3.19 ± 0.33 3.19 ± 0.34 3.53 ± 0.10 3.06 ± 0.58 3.18 ± 0.34 3.22 ± 0.46
Hematocrit (%) 41.69 ± 4.35 32.00 ± 4.75* 34.59 ± 5.64* 34.63 ± 5.08* 33.47 ± 3.35* 33.18 ± 5.98* 35.60 ± 8.58*
Heart rate (bpm/min) 177.15 ± 12.44 165.12 ± 25.95 164.39 ± 11.94 155.10 ± 13.34 154.41 ± 23.79 143.97 ± 20.74 155.98 ± 25.84
Stroke volume (mL) 1.34 ± 0.42 1.03 ± 0.44 1.13 ± 0.35 1.02 ± 0.19 1.35 ± 0.50 0.95 ± 0.42 0.95 ± 0.19
Left ventricle ejection fraction (%) 56.08 ± 5.8 52.67 ± 7.10 44.59 ± 5.9* 43.22 ± 4.10* 45.11 ± 6.20* 36.85 ± 9.38* 36.83 ± 2.34*
Cardiac output (mL/min) 237.84 ± 79.58 173.25 ± 90.00 186.85 ± 61.76 158.75 ± 37.41 204.31 ± 61.39 138.14 ± 60.18 155.98 ± 25.84
Left ventricle mass/weight (g/kg) 0.99 ± 0.24 0.98 ± 0.22 0.95 ± 0.17 0.90 ± 0.15 1.04 ± 0.30 0.92 ± 0.10 0.85 ± 0.83
Table 1. Physiological and functional data of all subjects. *Indicated p < 0.05. All data are expressed as 
mean ± SD.
Baseline subject Week 3 Week 6 Week 8 Week 10 Week 12 Week 16
(n = 16) (n = 6) (n = 10) (n = 6) (n = 7) (n = 8) (n = 4)
Native T1 value (whole myocardium) (ms) 1067.75 ± 24.08 1087.49 ± 46.13 1112.35 ± 38.36* 1097.48 ± 23.03* 1143.77 ± 33.29* 1124.92 ± 19.63* 1125.52 ± 10.82*
ECV (whole myocardium) (%) 27.95 ± 1.63 30.26 ± 1.28* 32.2 ± 1.29* 33.26 ± 0.84* 35.24 ± 1.45* 36.50 ± 1.36* 38.27 ± 0.68*
ECV (Upper RV insertion site) (%) 27.84 ± 1.25 31.69 ± 1.45* 33.36 ± 1.86* 34.77 ± 2.71* 36.26 ± 1.24* 37.91 ± 1.98* 39.09 ± 0.89*
ECV (Lower RV insertion site) (%) 28.73 ± 1.9 31.25 ± 2.91* 34.43 ± 1.78* 35.27 ± 2.48* 38.13 ± 2.43* 39.51 ± 2.89* 40.79 ± 0.98*
ECV (Papillary muscle) (%) 29.74 ± 2.37 33.48 ± 1.96* 35.01 ± 2.5* 36.11 ± 3.19* 39.55 ± 1.67* 41.61 ± 2.99* 43.69 ± 3.68*
Table 2. Cardiac magnetic resonance (CMR) data of all subjects.
Figure 2. Serial changes in the extracellular volume (ECV) and native T1 values. (a) Serial changes in the ECVs 
of the left ventricle (LV) myocardium and other specific LV lesions according to modelling time. The mean ECV 
of the mid-LV increased significantly beginning at 3 weeks (p = 0.002). Compared with the LV myocardium, the 
ECVs of the right ventricle (RV) upper and lower insertion sites and the papillary muscle were higher. (b) Serial 
changes in the native T1 values of the LV myocardium according to modelling time. Mean native T1 values at 
the mid-LV increased significantly beginning at week 6 (p < 0.001).
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Histology correlation. Myocardial injury was noted at an early modelling time point (week 3, Fig. 3b). 
Diffuse interstitial oedema was also noted in a 3-week model (Fig. 3c). The median myocardial score according to 
the modelling timeline is demonstrated in Table 3 and Fig. 3d. In baseline control subjects, microscopically, the 
LV myocardial interstitium contained minimal collagen fibres (Fig. 4a). Although even slight increases were not 
observed in the 3-week models (Fig. 4b), and in the 16-week model, abundant collagen deposition was observed 
in the myocardial interstitium (Fig. 4c). The median LV collagen volume fractions (CVFs) increased steadily 
according to modelling duration, and the mean CVFs at weeks 12 and 16 were significantly higher than the 
baseline (p = 0.020 and 0.003, respectively) (Table 3 and Fig. 4d). Although the ECV correlated positively with 
the histologic CVF (r = 0.979, p < 0.001), the native T1 value did not correlate with the histologic CVF (r = 0.455, 
p = 0.102). The RV insertion site had higher CVF values than the LV myocardium (p < 0.001), and the ECV of 
the RV insertion site correlated well with the CVF (r = 0.824, p < 0.001). Additionally, a correlation was observed 
between the myocardial injury score and degree of fibrosis according to the modelling time (r = 0.59, p = 0.02).
Diagnostic value of T1 mapping parameters. In the first analysis, post-modelling subjects (3-, 
6-, 12-, 16-week models) were considered disease-positive and used to confirm the ability to detect early 
anthracycline-induced cardiotoxicity. The areas under the receiver operating characteristic (ROC) curves (AUCs) 
Figure 3. Histological findings of myocardial injury. (a) Normal myocardium from a control subject. (b) Severe 
myocardial injury with intracytoplasmic vacuolization (arrowheads) and myofibril loss (arrows) are visible 
in the left ventricular (LV) septal wall of a 3-week model (myocardial injury score = 3). (c) Diffuse interstitial 
oedema is visible in the LV lateral wall of a 3-week model. Haematoxylin and eosin staining; magnification, 
×400 (d) Myocardial injury score according to the modelling time.
Baseline subject Week 3 Week 6 Week 12 Week 16
(n = 16) (n = 6) (n = 10) (n = 8) (n = 4)
CVF (%) [LV myocardium, 
median (range)] 3.04 (2.67–4.15)
† 7.78 (6.86–8.47)† 10.67(10.14–11.21)‡ 19.23 (16.87–28.84)*,§
33.17 (19.21–
39.86)*,§
CVF (%) [RV insertion, 
median (range)] 5.69 (4.57–6.63)
† 9.69 (9.65–10.01)† 15.72 (14.83–16.61)‡ 29.44 (17.82–30.01)*,§
46.01 (18.71–
51.76)*,§
Myocardial injury score 
[median (range)] 0 (0–0) 0.5 (0.5–1.25)
† 0.5 (0–1)‡ 1.125 (0.75–1.5)§ 1.0 (1–1)§
Table 3. Histologic data of all subjects. *Indicated p < 0.05. †Indicated n = 3, ‡indicated n = 2, §indicated n = 4.
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of the ECV, native T1, and LVEF were 0.974 (95% CI, 0.955–0.989), 0.893 (0.848–0.930), and 0.916 (0.874–0.951), 
respectively (Fig. 5a). The AUC of the ECV differed significantly from those of the ejection fraction (EF; p = 0.001) 
and native T1 (p < 0.001), whereas the AUCs of the native T1 and EF did not differ significantly (p = 0.051). In 
the second analysis, which set the disease onset at 12 weeks of modelling after observing a significant increase in 
CVF at this time point, the AUCs of the ECV, native T1, and LVEF were 0.981 (95% CI, 0.969–0.990), 0.882 (95% 
CI, 0.855–0.910), and 0.857 (0.801–0.906), respectively (Fig. 5b). Here, the AUC of the ECV was found to differ 
significantly from that of the EF (p < 0.001) and native T1 (p < 0.001); again, the AUCs of the native T1 and EF 
did not differ significantly (p = 0.821).
Discussion
The present study aimed to assess the diagnostic feasibility of T1-mapping CMR for the evaluation of early myo-
cardial changes in a rabbit model of doxorubicin-induced cardiotoxicity. Notably, in this model, the ECV changed 
significantly beginning at week 3 of modelling, or earlier than the observed changes in the native T1 and LVEF. 
Accordingly, the ECV had a higher diagnostic value than either the native T1 value or LVEF, and correlated well 
with the histology findings.
Doxorubicin, a representative anthracycline, is highly effective against a broad spectrum of malignancies, 
including lymphoma, sarcoma, and breast cancer, as well as other malignancies that occur in young female 
patients4, 12. Given its status as the most commonly used chemotherapeutic agent in cancer patients and the 
increasing cancer survival rate, the clinical significance of anthracycline-induced cardiotoxicity is expanding12.
Anthracycline-induced cardiotoxicity is considered a continuum that begins with subclinical myocardial cell 
injury and, leads to an early asymptomatic decline in LVEF that can develop into symptomatic heart failure13. The 
early detection and treatment of cardiotoxicity is critical for the recovery of cardiac function and reduction in the 
incidence of associated adverse cardiac events13, 14. Although the need for cardiac monitoring of asymptomatic 
anthracycline-treated adult patients is generally acknowledged, the existing guidelines offer no clear consensus 
regarding the timing or duration of such surveillance14, 15.
Currently, LVEF identification is most commonly used to screen for cardiotoxicity. Although MUGA scans 
and echocardiography are widely used to monitor the EF in cancer patients7–9, 16, 17, these methods are associated 
with a low sensitivity and specificity17; in addition, functional approaches cannot detect subclinical cardiac dam-
age before an apparent and irreversible decrease in cardiac function. Accordingly, additional strategies for the 
early detection of cardiac damage and monitoring of treatment-induced cardiotoxicity are needed16. In this light, 
Figure 4. Histological images of extracellular collagen deposition in the left ventricle (LV) myocardium. (a) 
Minimal collagen fibres are visible in the interstitium of a baseline subject (measured collagen volume fraction 
[CVF] = 3.04%). (b) No significant increase in collagen fibres was observed in a 3-week model (CVF = 4.28%). 
(c) Abundant collagen deposition is visible in a 16-week model (CVF = 25.00%). Picrosirius red staining; 
original magnification, ×200 (d) Myocardial fibrosis according to the modelling time.
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T1 mapping has emerged as a promising quantitative method for the detection of subclinical myocardial changes 
in various cardiomyopathies18, 19. Furthermore, T1 mapping and ECV measurement have been considered prom-
ising tools for the detection and quantification of myocardial damage resulting from chemotherapy-induced car-
diotoxicity10, 11.
In our study, we observed changes in myocardial ECV without detectable changes in LVEF in early models; 
specifically, the ECV changed significantly at 3 weeks after model induction, whereas significant changes in the 
LVEF and native T1 were not observed until after 6 weeks. Furthermore, the mean CVFs of the LV were signif-
icantly higher than the baseline at 12 weeks. Small differences in native T1 between the normal and abnormal 
myocardium may be a cause of a later elevation of native T1.
Anthracycline-induced chemotoxicity results from the production of free radicals in both normal and malig-
nant cells; these radicals react with oxygen to produce superoxide anion radicals, which damage the collagen 
network and cardiomyocytes20, 21. Previous studies demonstrated that at the tissue level, early anthracycline 
toxicity is associated with myocardial inflammation, vacuolization, cell swelling, and oedema, and that these 
changes occur before the onset of myocardial dysfunction22, 23. Our study also demonstrated tissue changes in 
early anthracycline toxicity models (i.e., week 3), particularly degenerative myocardial changes, vacuolization, 
and interstitial oedema. Notably, all of these types of damage, other than fibrosis, would cause an increase in the 
ECV in early models20, 23. The process of myocardial injury, which was quantitatively evaluated using Billingham 
scores, was also found to begin at week 3 along with the elevation of the ECV, thus corresponding to the sub-
clinical stage before the LVEF and CVF changed significantly. In other words, myocardial injury preceded the 
development of fibrosis, and the myocardial ECV might reflect subclinical myocardial injury resulting from 
anthracycline-induced cardiotoxicity. An ECV based on a T1 mapping sequence could serve as an early marker 
of myocardial damage.
In our study, the CVF was higher in the RV insertion sites than in the LV throughout the modelling period. 
The RV and right atria are known to have significantly higher collagen concentrations than the LV and left atria24, 
25. A previous study reported that because of this higher collagen concentration, the RV has a significantly higher 
myocardial native T1 value than the LV24. Notably, the RV and LV myocardium are combined at the RV inser-
tion site, and accordingly this site had a higher CVF when compared with other parts of the myocardium. Our 
results also demonstrated that the papillary muscle had the highest ECV among all LV areas. An increase in the 
amount of abnormal collagen in the papillary muscle in response to chemotherapy-induced cardiotoxicity would 
greatly impair the contractile capacity and electrical conductance, thus severely compromising cardiac function26. 
However, even analyses of RV insertion sites and papillary muscles are not critical to a diagnosis of cardiotoxicity. 
Such a diagnosis might be facilitated by an additional focus on subclinical cardiotoxicity in cases without appar-
ent myocardial fibrosis.
The strengths of our study included the availability of serial data based on the modeling time and a histologic 
evaluation of the myocardial structure. Our results also demonstrated that T1-mapping CMR could detect early 
myocardial damage.
Additionally, native T1 and the ECV might facilitate the detection of anthracycline responders before LV func-
tional impairment becomes evident, and thus allow therapeutic adjustments and consideration of other treatment 
regimens. Further studies are required.
We also note several limitations of our study. First, the sample size was small, and our inclusion of extreme 
injury models led to a high incidence of severe cardiotoxicity, which could be considered a potential weakness. 
Further study is required to evaluate the incidence of cardiotoxicity in patients who exhibit early increases in ECV 
Figure 5. Receiver operating characteristic (ROC) curves for diagnosis. (a) Areas under the ROC curves 
(AUCs) for the extracellular volume (ECV), native T1, and left ventricle ejection fraction (LVEF) in post-
modelling subjects were 0.974 (95% confidence interval, 0.955–0.989), 0.893 (0.848–0.930), and 0.916 (0.874–
0.951), respectively. (b) In 12- and 16-week modelling subjects, the AUCs for the ECV, native T1, and LVEF 
were 0.981 (0.969–0.990), 0.882 (0.855–0.910), and 0.857 (0.801–0.906), respectively.
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while receiving clinical doses of chemotherapy, as well as the prognostic value of an early increase of ECV in the 
clinical patient group.
Second, in the statistical analysis, we did not correct the significance level (e.g., Bonferroni adjustment) for 
multiple comparisons in the post hoc analysis. Some results with p-values near 5% might therefore be false posi-
tives. A further confirmatory study involving a larger sample size is needed to confirm the ability of our method to 
detect anthracycline-induced cardiotoxicity. Third, the small size of the papillary muscle precluded an evaluation 
of CVF. Finally, the control group was limited and did not include animals subjected to placebo treatment; rather, 
this group comprised all animals that underwent pre-modelling CMR. However, the use of the same animals 
in both groups allowed us to compare the baseline and serial data from each modelling time point in the same 
subject.
In conclusion, myocardial T1 mapping is a reliable and non-invasive method for the detection and serial mon-
itoring of cardiotoxicity. This technique could form the basis of an appropriate strategy for the early detection of 
subclinical cardiotoxicity, even before a conventional critical doxorubicin dose has been reached.
Methods
Animal model and drug administration. All experiments were approved by animal care and use com-
mittee (IACUC) of Yonsei University Health System (approval number: 2014–0388) and were performed accord-
ing to National Institutes of Health guidelines27. Twenty rabbits (adult male New Zealand White; body weight: 
3–4 kg) were included in this study. Three rabbits were sacrificed after initial scanning to provide baseline histo-
logical findings. The remaining 17 rabbits received 1.0-mg/kg injections of doxorubicin (doxorubicin hydrochlo-
ride; Cayman Chemical, Ann Arbor, MI, USA) twice weekly until the time of sacrifice for histological evaluation. 
We followed a protocol that involved the lowest mortality rate in our previous study28. Although doxorubicin is 
known to be particularly venotoxic29, we did not experience difficulties with preserving vein integrity and did not 
encounter problems such as vein or skin necrosis during the maximum study period of 16 weeks.
Animal preparation before CMR examination. Rabbits underwent MR examinations prior to drug 
administration to provide baseline data, followed by MR examinations 3 weeks after the first doxorubicin injec-
tion and every 2 weeks thereafter until the end of the specific post-modelling time period. Before each MR 
examination, rabbits were anesthetized with an intra-muscular injection of tiletamine (30 mg/kg, Zoletil; Vibac 
Laboratories, Carros, France) and xylazine (5 mg/kg, Rompun; Bayer, Seoul, Korea). The auricular veins of each 
rabbit were prepared for contrast injection. Venous sampling was performed to determine the haematocrit (Hct) 
values of all rabbits immediately before the MR examinations. After anaesthesia induction, the animals were intu-
bated and mechanically ventilated (Mekant, MEKICS, Seoul, Korea) using a mixture of oxygen and isoflurane.
CMR protocol. CMR was performed using a 3-T MR scanner (Magnetom Trio Tim; Siemens Healthcare, 
Erlangen, Germany) with a six-channel anterior body matrix coil and posterior part of a 12-channel head matrix 
coil. Cardiac localization was achieved using a steady-state free-precession sequence under electrocardiogram 
(ECG) gating. Pre- and post-contrast T1 mapping, cine, and late gadolinium enhancement (LGE) images were 
acquired. T1 mapping was performed using a prototype modified Look–Locker inversion recovery (MOLLI) 
sequence during the end-expiratory period in the mid-ventricular short-axis view. Pre-contrast T1 mapping 
images were acquired before contrast injection. Post-contrast T1 mapping images were acquired 13 min after 
the intravenous injection of a 0.2-mmol/kg dose of gadolinium contrast agent (Omniscan®; GE Healthcare, 
Princeton, NJ, USA). LGE MR imaging was obtained 15 min after contrast agent injection using a magnitude- 
and phase-sensitive inversion recovery-prepared steady-state free-precession sequence, with the inversion time 
adjusted to nullify the normal myocardium (please refer to the supplemental materials for the detailed CMR 
protocol).
Image analysis. Two radiologists (Y.J.H., C.H.P.) with 10 years of experience in cardiovascular image inter-
pretation analysed all MR images.
Functional MR image analysis. All MR cine images were transferred to cvi42 image analysis software (Circle 
Cardiovascular Imaging Inc., Calgary, AB, Canada). The LV function was assessed on short-axis cine MR 
images according to Simpson’s method. The endocardial and epicardial borders of the LV wall were delineated 
semi-automatically on end-diastolic and end-systolic images. The LV end-diastolic volume and LV end-systolic 
volume were automatically measured, and the LV ejection fraction (LVEF, %) and LV mass/weight (g/kg) were 
calculated.
CMR image analysis for the measurement of T1 and ECV fraction (%). All MR pre- and post-contrast 
T1-mapping images were transferred to cvi42 image analysis software. For a regional analysis of the LV myo-
cardium, the endocardial and epicardial borders of the LV wall were delineated semi-automatically on pre-and 
post-contrast T1 images obtained in a short-axis plane at the mid-LV level and divided into six segments based on 
AHA recommendations. A round, <5 mm2 region of interest (ROI) that avoided the papillary muscle was drawn 
in the LV cavity (Fig. 6a,b). Pre- (native) and post-contrast T1 values of the LV and blood cavity were measured 
automatically. The myocardial ECV was also calculated automatically using the Hct value and the native and 
post-contrast T1 values of the LV myocardium and blood cavity, as follows:
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The mean native T1 and ECV values of each segment were used. The native T1 and ECV were also measured 
at specific LV lesions, upper/lower RV insertion sites, and the papillary muscle. ROIs covering specific lesions 
(2–3 mm2) were drawn, and the pre- and post-contrast T1 and ECV values of specific lesions and the LV cavity 
were measured automatically (Fig. 6c,d).
Histological analysis. After undergoing a final post-model MR scan, each rabbit was euthanized via potas-
sium chloride while in an unconscious state induced by tiletamine/xylazine (30/5 mg/kg IM). The heart was 
extracted immediately after euthanasia for histologic evaluation. Each heart was fixed in 10% phosphate-buffered 
paraformaldehyde. After 1 week of fixation, the heart was sectioned serially along the short-axis plane using a rab-
bit heart slicer (Zivic Instruments, Pittsburgh, PA, USA), and the entire section of the heart at the mid-ventricle 
level, wherein papillary muscles were visible, was embedded in paraffin. Four-micrometre-thick slices of this sec-
tion were obtained, stained with haematoxylin and eosin (H&E) and picrosirius red, and subsequently examined 
by a pathologist (H.S.P) blinded to the MR results.
Myocardial injury analysis. H&E staining was used to evaluate myocardial injury. The degree of myocardial 
injury was evaluated using a light microscope (optical BX 53 microscope; Olympus, Tokyo, Japan) and scored 
according to a seven-point scale described by Billingham et al.4, 22. Twelve sets of LV myocardium micrographs of 
(three each of the septum, lateral, superior, and inferior wall) were analysed per animal. The grading system was 
Figure 6. Measurement of T1 values in the myocardium and specific lesions of the left ventricle (LV) at the 
mid-ventricle on the short-axis plane. Endocardial (red line) and epicardial borders (green line) of the LV wall 
were delineated semi-automatically; six segments were delineated automatically (white lines). A round <5 mm2 
region of interest (ROI; orange circle) was drawn in the LV cavity on pre-contrast (a) and post-contrast T1 
mapping images (b). To measure T1 values of specific LV lesions in the short-axis plane, ROIs covering specific 
lesions (blue circle 1: right ventricle (RV) upper insertion site, 2: RV lower insertion site, 3: papillary muscle) 
were drawn on pre-contrast (c) and post-contrast T1-mapping images (d).
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as follows: 0 = no damage; 0.5 = not completely normal; 1, 1.5, 2, 2.5, and 3 = damage to 1–5%, 6–15%, 16–25%, 
26–35% and >35% of all cells, respectively.
Collagen volume fraction (CVF, %) analysis. Picrosirius red staining was used to evaluate the CVF in the extra-
cellular space. Twelve sets of LV myocardium micrographs (three each of the septum, lateral, superior, and infe-
rior wall; magnification, ×200) and six fields from the RV upper and lower insertion sites (magnification, ×400) 
were acquired per animal and transferred to a computer for further analysis. The mean percentage of fibrosis was 
also determined. Perivascular fibrosis was not included in this analysis18 (please refer to the supplemental mate-
rials for a detailed protocol).
Statistical analysis. All continuous data are expressed as means ± standard deviations, and categori-
cal variables are presented as numbers or percentages. The Shapiro–Wilk test was performed to evaluate data 
distributions.
A linear mixed model with restricted maximum-likelihood estimation was used to evaluate the time point of 
each variable (Hct, LV mass, LV mass/kg, EF, CVF, myocardial injury score) and the native T1 and ECV values 
of the whole LV and specific LV lesions (RV insertion sites, papillary muscles) in each experimental group that 
exhibited a significant change from the baseline group according to the modelling time. The MIXED protocol in 
SAS (version 9.2; SAS Institute, Cary, NC, USA) was used to generate this linear mixed model, which included 
fixed effects for time and specific lesions, interactions between time and specific lesions, and random intercepts 
for each animal. Time was considered a categorical variable in this model, and equal covariance was assumed 
between all-time points.
To compare the diagnostic performances of ECV, native T1, and LVEF, a ROC curve was constructed30. 
Post-modelling groups were considered positive for disease. A bootstrap method with 1,000 replications was used 
for an evaluation that yielded a 95% confidence interval (CI) and p value of the AUC. Spearman’s correlation was 
used to compare the ECV values of the LV myocardium and RV insertion site (mean ECV of the RV upper and 
lower insertion sites), as well as the myocardial injury scores and histologic CVFs. The CVFs of the LV myocar-
dium and RV insertion site were compared using a paired t test. Inter-observer agreement regarding the measured 
native T1 and ECV values of the LV and specific lesions was assessed using ICCs, as well as a two-way random 
effects model that included the observer and animal as random effects. All statistical analyses were performed 
using SAS, and a p value < 0.05 was considered statistically significant.
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